“That’s why,” says Dr Naval Vikram Kishore, professor of medicine, Metabolic Research Group, AIIMS, “obesity has to be ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

Juvenile idiopathic arthritis is the most common chronic systemic disease associated with uveitis in childhood. Uveitis occurs in 11–22% of children with juvenile idiopathic arthritis.1 Due to the ...

We thank the authors for their interest in our paper, and their queries. In response to Yue Li and Guangsen Liu, given the current situation of malaria deaths and cases increasing in recent years,1 it ...

Following the Trump administration's DEI ban, the FDA's move to scrub webpages has ensnared many pages focused on ensuring diversity in drug trials.

Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for ...

Study participants in the PK run-in study are randomized 2:1 to receive either nomlabofusp or placebo daily for seven days. Following assessment of safety and PK data of each successive cohort, ...

In the Phase I dose escalation portion, which evaluated the combination in participants with small cell lung cancer, the first patient treated attained partial remission.

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.